In pre-clinical cancer therapy research, CYP24A1 inhibitors are able to reduce the breakdown of 1,25 (OH)2D and enhance its anti-tumor effect, and show potential therapeutic value. This evidence concerns the gene CYP24A1 and neoplasm.